Alvotech
Alvotech, officially known as Alvotech Holdings SA, is a prominent biopharmaceutical company headquartered in Luxembourg (LU). Founded in 2013, Alvotech focuses on the development and manufacturing of high-quality biosimilars, addressing the growing demand for affordable biologic therapies. With a strong operational presence in Europe and North America, the company has established itself as a key player in the biosimilars market. Alvotech's core offerings include a diverse portfolio of biosimilar products that are distinguished by their rigorous development processes and commitment to quality. The company has achieved significant milestones, including successful regulatory approvals and partnerships that enhance its market position. Recognised for its innovative approach, Alvotech continues to lead in the biopharmaceutical industry, striving to improve patient access to essential therapies.
DitchCarbon Score
How does Alvotech's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Alvotech's score of 36 is higher than 98% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Alvotech's reported carbon emissions
In 2023, Alvotech reported total carbon emissions of approximately 923,000 kg CO2e. This figure includes 20,000 kg CO2e from Scope 1 emissions, which encompass direct emissions from owned or controlled sources, and 209,000 kg CO2e from Scope 2 emissions, primarily related to purchased electricity. The majority of their emissions, about 555,000 kg CO2e, fall under Scope 3, which includes indirect emissions from business travel, waste generated in operations, and fuel and energy-related activities. In comparison, emissions in 2022 were approximately 957,000 kg CO2e, with Scope 1 at 19,000 kg CO2e, Scope 2 at 217,000 kg CO2e, and Scope 3 at 721,000 kg CO2e. The trend shows a slight decrease in total emissions from 2022 to 2023, although the overall figures remain significant. Alvotech has not publicly disclosed specific reduction targets or initiatives aimed at decreasing their carbon footprint. However, they are committed to transparency in their emissions reporting, covering all three scopes of emissions. The company continues to monitor and report its emissions data, reflecting its awareness of climate impact and the importance of sustainability in the biopharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 16,000 | 00,000 | 00,000 | 00,000 |
| Scope 2 | 202,000 | 000,000 | 000,000 | 000,000 |
| Scope 3 | 261,000 | 000,000 | 000,000 | 000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Alvotech is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
